Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal

While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals

Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.

Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More

Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.

Gilead (GILD) Down 7% Since Last Earnings Report: Can It Rebound?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22

Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 2022.

Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

Gilead (GILD) Veklury Retains Activity Against Omicron Variant

Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q4 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More

Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.

Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges

Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.

Gilead Sciences (GILD) Q4 Earnings Miss Estimates

Gilead (GILD) delivered earnings and revenue surprises of -54.90% and 9.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Big Data for Q4, Econ to Start a New Month

We've got a big day ahead with both economic prints and Q4 earnings reports.

Wall Street Waits for Major Economic Data This Week

Wall Street Waits for Major Economic Data This Week.

Should Value Investors Pick Gilead Sciences (GILD) Stock?

Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.

Should You Buy Gilead Sciences (GILD) Ahead of Earnings?

Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid

Pfizer's (PFE) oral COVID-19 drug, Paxlovid, gets recommendation from the CHMP for its authorization in Europe for treating mild-to-moderate COVID-19 in patients at increased risk of hospitalizations.

Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.

Nalak Das headshot

5 Corporate Giants Likely to Gain From Q4 Earnings Next Week

Five corporate behemoths will report fourth-quarter 2021 earnings results next week. These are: TMO, FB, GOOGL, GILD and UPS.

Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More

Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.

Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA

Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.

The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead

Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.